General Electric is launching healthcare initiatives in Africa in partnership with governments and a $20 million commitment from the GE Foundation to improve the continent's healthcare. Most notably, the GE Foundation is funding a $1.5 million biomedical training program in Nigeria to ensure that the country has technicians who can fix devices ranging from blood pressure cuffs to X-rays.
On Friday, 19-year-old Harvey Humphrey visited his parents, the husband-and-wife team of private detectives who did investigative work for GlaxoSmithKline's disgraced China office, for the first time since they were detained by Chinese police last summer. The family saga painfully illustrates the potential pitfalls of doing business in China.
Sanofi's in line to rack up blockbuster sales after hitting a wide-open market with its dengue vaccine, analysts predict. And company CEO Chris Viehbacher thinks those sales could start rolling in before next year is out.
The chilly sales climate in China is just now warming up after last summer's wave of bribery accusations spooked doctors and sales reps. But as far as Merck KGaA is concerned, China is warm enough to deliver doubled revenues in the region. And that's exactly what the German drugmaker's shooting for.
Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.
Sales of products for the production animal category in emerging markets were up significantly for French drugmaker Virbac in the first half. It was helped in South America by the integration of Uruguay-based Santa Elena, which it bought last year, but it was not enough to overcome difficult foreign exchange rates and weak sales in the U.S. after having to recall 34 lots of its Iverhart Plus chewable heartworm medicine last year.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.
GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $489 million scandal that broke last summer. The U.K. company has acknowledged that it fired about 30 staffers in its China vaccines business in 2001 after turning up evidence of corruption.
As polio flare-ups in central Asia, the Middle East and Central Africa continue, a new study suggests that an extra dose of the inactivated polio vaccine could further protect children under 5 years old in high-risk countries.
The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.